// App-Quantinova.ai

TPS3160 : A phase Ib, open-label, dose-escalation trial of naptumomab estafenatox (Nap) in combination with durvalumab (MEDI4736) in subjects with selected advanced or metastatic solid tumors.

Researchers

Presenter

  • Ravit Geva

Principal Investigators

  • Corinne Maurice-Dror

  • Mor Tal Moskovitz

  • Eitan Ben-Ami

  • Ari Raphael

  • Ilana Lorber

  • Marcel Rozencweig

  • Talia Golan

Medical Centers

  • Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel

  • Rambam, Haifa, Israel

  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel

  • NeoTx LTD, Rehovot, Israel

  • INNATE Pharma, Princeton, NJ

  • The Oncology Institute, Sheba Medical Center at Tel-Hashomer, Tel Aviv University, Tel Aviv, Israel

Locations

  • Israel

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • naptumomab estafenatox

  • Durvalumab

Outcome

  • N/A

Study Design

  • Open Label

  • Dose Escalation

  • Cohort

Phase

  • NA

Study Id's

  • NCT03983954

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved